Syngene International Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9eeas5vz4mht4jdriun5u9gg.pdf

Key Takeaways


Demand Environment

Hunt: "While the fourth quarter performance came in lower than expected, the underlying driver - reduced demand for research and development services within US biotech stemming from a difficult funding environment - is well understood and already showing positive signs of recovery."

Margin & Cost Structure


Biologics Manufacturing Build-Out

Biswas: "Our net cashflow generated from operating activities for the year was strong at Rs 1,042 Crores, which fully funded the capex and the acquisition of the biologics manufacturing plant."

Capability & Platform Investments


Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growthHigh single digits to low double digits, momentum building during the yearFY25
EBITDA marginSimilar to FY24 levelFY25
PAT growthSingle digitsFY25
Stelis facility operationalQualification and facility modifications complete; drug substance and drug product productionH2 2024
Demand recoveryRecent US biotech funding step-up to drive R&D services demand recoveryLatter part of FY25

Key Metrics

MetricQ4 FY24
Revenue from operations₹917 Cr, down 8% YoY
Reported revenue (incl. other income)₹933 Cr, down 8% YoY
Reported EBITDA₹333 Cr, down 1% YoY
EBITDA margin36%, up from 33% in Q4 FY23
PAT before exceptional items₹189 Cr, up 6% YoY
PAT margin20%, up from 18% in Q4 FY23
EBITDA from operations₹317 Cr, up 0.9% YoY
EBITDA from operations margin34.6%, up 298 bps YoY
EBIT from operations₹206 Cr, down 5.8% YoY
EBIT from operations margin22.5%, up 48 bps YoY
FY25 revenue growth guidanceHigh single digits to low double digits, momentum building during the year
FY25 EBITDA margin guidanceSimilar to FY24 level
FY25 PAT growth guidanceSingle digits
Final dividend per share₹1.25, up 150% over FY23 core dividend of 50 paise
Net cashflow from operating activities (FY24)₹1,042 Cr, fully funded capex and biologics plant acquisition